AbbVie, Emblaveo

AbbVie gets USFDA nod for Emblaveo for treatment of adults with complicated intra abdominal infections with limited or no treatment option
AbbVie has announced that the U.S. Food and Drug Administration (FDA) has approved EMBLAVEO (aztreonam and avibactam), as a fixed-dose, intravenous, monobactam/β-lactamase
US FDA approves AbbVie-Pfizer's treatment for intra-abdominal infections
AbbVie said on Friday that the U.S. Food and Drug Administration approved its drug for complicated intra-abdominal infections, including those caused by drug-resistant bacteria. AbbVie and co-developer Pfizer's drug,
AbbVie: FDA Approves Emblaveo - Metronidazole Combination For Complicated Intra-Abdominal Infections
AbbVie (ABBV) announced the U.S. Food and Drug Administration approval of Emblaveo (aztreonam and avibactam). This marks the first
AbbVie gets FDA approval for antibiotic treatment Emblaveo (update)
AbbVie (ABBV) said it has received FDA approval for the combination antibiotic treatment Emblaveo, which was co-developed with Pfizer (PFE). Read more here.
FDA approves novel antibiotic EMBLAVEO for cIAI
NORTH CHICAGO, Ill. - The U.S. Food and Drug Administration (FDA) has approved EMBLAVEO™ (aztreonam and avibactam) for the treatment of adults with complicated intra-abdominal infections (cIAI) with limited or no treatment options,
AbbVie says FDA approves Emblaveo in combination with metronidazole in adults
AbbVie (ABBV) announced that the U.S. Food and Drug Administration has approved EMBLAVEO, as the first and only fixed-dose, intravenous,
AbbVie Gets FDA Approval of Intravenous Antibiotic Emblaveo
AbbVie received Food and Drug Administration approval of Emblaveo, an intravenous antibiotic, for treatment of adults with complicated intra-abdominal infections with limited or no treatment options. The drug, which combines aztreonam and avibactam, was approved in combination with metronidazole.
FDA approves Emblaveo for complicated intra-abdominal infections
The FDA has approved the intravenous antibiotic Emblaveo for adults with complicated intra-abdominal infections who have limited treatment options.
Crain's Chicago Business12h
AbbVie gets FDA OK on antibiotic therapy that fights resistant bacteria
It's the first and only such therapy approved to fight antimicrobial resistance, or AMR, in bacterial infections.
AOL7d
AbbVie (ABBV) Earnings Live: Why The Stock Is Up Big Today
Shares of AbbVie (NYSE:ABBV) are surging 7% this morning after the pharmaceutical giant reported solid fourth quarter earnings as two key immunology drugs continue to enjoy significant support.